Claudia Baratè

All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.

4. Discussion CLL remains a malignancy largely incurable despite advances in new treatment options [5]. In R/R patients, BTKi ibrutinib is an effective therapeutic option [24], but it requires extended administration until unacceptable toxicity or disease progression. Fixed duration therapies may achieve deep and durable clinical responses and may reduce the development of resistant sub clones [25].

Abstract Objectives Polycythemia vera (PV) is an acquired clonal hematopoietic stem cell disorder characterized by overproduction of red blood cells. It has long been underlined that there are differences in treatment patterns in routine practice. Therapeutic strategies have also expanded, and in recent years the JAK1/JAK2 inhibitor ruxolitinib has emerged as a second line therapeutic option in patients who are intolerant to or resistant to hydroxyurea.